Altre lingue Biofrontera AG

Azioni

Tempo differito Xetra Altri mercati azionari 17:36:21 24/04/2024			Variaz. 5gg	Var. 1 gen.
0,334 ^EUR	-3,47%		-4,57%	-16,71%

11/03	Biofrontera deposita un prospetto per una potenziale offerta di azioni secondarie	MT
2023	Biofrontera AG riporta i risultati degli utili per il terzo trimestre e i nove mesi conclusi il 30 settembre 2023	CI

Biofrontera : Abstimmungsergebnisse	04/04
Biofrontera Files Prospectus for Potential Secondary Stock Offerings	11/03
Medicus Pharma Names COO	05/03
BIOFRONTERA AG ANNOUNCES REVISED STRATEGY	21/02
BIOFRONTERA AG, BIOFRONTERA TRANSFERS CLINICAL RESEARCH TO THE U.S.	21/02
MORNING BRIEFING - Deutschland/Europa -2-	16/02
Biofrontera AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	28/11
Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $8.9M, vs. Street Est of $8.4M	09/11
Biofrontera Licensor Gets FDA Approval for New Formulation of Ameluz to Treat Actinic Keratosis	10/10/23
Biofrontera Says Sun Pharmaceutical Alleging Breach of Contract In Lawsuit	03/10/23
Biofrontera AG Reports Earnings Results for the Half Year Ended June 30, 2023	31/08/23
Biofrontera Says Skin Disease Therapy Was Well-Tolerated in Phase 1 Safety Trial	28/08/23
Earnings Flash (BFRI) BIOFRONTERA Reports Q2 Revenue $5.8M	11/08/23
Biofrontera Completes Patient Enrollment in Skin Cancer Treatment Study	10/08/23
Top Premarket Decliners	21/07/23
Biofrontera Launches Novel Belixos Active Care	05/07/23
Biofrontera to Effect 1-for-20 Reverse Stock Split	03/07/23
Wall Street Set to Open Lower; Housing Starts Rise More Than Expected	20/06/23
Biofrontera AG Reports Earnings Results for the First Quarter Ended March 31, 2023	31/05/23
Biofrontera AG Completes Patient Recruitment of Ameluz Phase I Trial	17/05/23

Non ci sono risultati per questa ricerca